

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

PROFIT WARNING

This announcement is made by PuraPharm Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors of the Company (the “**Directors**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2025 (“**2025 Interim Period**”) and other information currently available to the Board, it is expected that the Group will record a net loss of approximately HK\$24 million for the 2025 Interim Period, as compared to the consolidated net loss of approximately HK\$18.7 million recorded for the corresponding period ended 30 June 2024.

Based on the information currently available, the Board believes that the expected net loss in the 2025 Interim Period is mainly attributable to the decrease in revenue and an increase in the cost of goods sold, which put pressure on the gross profit of the Group during the 2025 Interim Period. The decrease in revenue was principally due to the slowing down of consumption in Hong Kong and keen market competition, while the cost of goods sold increases due to higher raw material prices, environmental challenges and decrease in production volume.

The Company is still in the process of finalising the interim results of the Group for the 2025 Interim Period. The information contained in this announcement is only based on the preliminary assessment by the Board with reference to the information currently available, including the unaudited consolidated management accounts of the Group for the 2025 Interim Period, which are yet to be finalised and have not been reviewed or audited by the Company's auditor or reviewed by the audit committee of the Board and are subject to adjustments. The actual interim results of the Group for the 2025 Interim Period may be different from the information disclosed in this announcement. Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for the 2025 Interim Period, which are expected to be published by the end of August 2025 in accordance with the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman and executive Director

Hong Kong, 24 July 2025

As at the date of this announcement, the executive Directors are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Tsoi Kam Biu, Alvin; the non-executive Director is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors are Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.